Generics News

Natco Pharma is exploring opportunities beyond generic drugs for future growth, as explained by CEO and Vice Chairman Rajeev Nannapaneni. He detailed how Indian

Biocon's Kiran Mazumdar-Shaw believes US generics tariffs are more of a negotiation tactic than a real threat, with the company exploring potential manufacturin

Aman Mehta, MD of Torrent Pharmaceuticals, discusses the company's future growth strategy, focusing on transitioning from generics to drug innovation to become

Ozempic saw a 50% jump in sales despite losing its patent, attributed to Novo Nordisk's strategy of slashing prices to compete with generic versions.

Three determined individuals invested $1.5 billion over two decades to focus on drug discovery in India, rather than just producing generics. Their long-term co

Pharma companies are facing uncertainty due to former President Trump's proposed 200% tariff on generic drugs.

Shares of Sun Pharma, Aurobindo, Lupin, and Zydus Life are in focus following Trump's announcement of a two-year zero tariff policy on generics. US exports cons

The Semaglutide situation has exposed systemic weaknesses in India's pharmaceutical industry, potentially proving costly for the country's generics sector.